CTLA4 and neoplasm: There has been significant progress in the development of immune checkpoint inhibitors (ICIs) that promote the anti-tumour activity of T cells by inhibiting immune checkpoints such as programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4).